Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Corvus Pharmaceuticals, Inc
This is a non-randomised, dose escalation and expansion trial. Eligible patients will receive CPI-818 capsule twice daily at an assigned dose until disease progression, complete response or remission for more than 2 months or if the assigned dose is determined to be unsafe.